RE:Time for growthTheir plan for growth is internally funded by current operations and cash on hand. Potential scaling up for Y-BG as an immune booster can be accomplished with only $4M of capital. Beyond 2024, if plans are to proceed wtih 40M doses of this product, that would require $40M of investment at which time they can look at financing options.
As for now, no need to dilute shareholders. It's all laid out in the SCD interview.